Tempus is a data-driven tech company co-founded out of Chicago by entrepreneur Eric Lefkofsky. The company was established in 2015 and over the past several years the team at Tempus has been hard at work trying to improve the way that cancer care is addressed in America. In order to do this, Tempus has been working on revolutionizing the way that data is acquired and dispersed to medical providers and patients alike. Tempus recently made the news for another round of successful investing efforts, bringing in an additional $80 million through another group of investors, and now their platform is starting to really grow.
Addressing how patients and healthcare professionals handle data is an important topic of discussion that does not get nearly enough attention. Lefkofsky saw how important having accurate and efficient data was, seeing it up close himself, and he has since been working to make Tempus part of the problem-solving process. Tempus employs roughly 400 employees and the company seems like it won’t be slowing down anytime soon with nearly 30 employees per month being added to the roster.
What Tempus is doing, in essence, is making it possible for accurate data to be put where it needs to go in order for it to have the greatest impact. Tempus collects clinical data before digitizing it in order to look for trends in the cancer care field. Tempus also pulls in molecular data from patients that are actively undergoing treatment. Data collection, as any Silicon Valley professional will admit, is an incredibly important area of expertise in today’s digital age. This data can be pooled from something as simple as a handwritten patient note all the way to an expansive and extensive database.
The new round of investors will help to keep Tempus trending forward as they continue to grow at an astronomic rate. Among the newest investors are New Enterprise Associates, Kinship Trust Co, and T. Rowe Price Associates. Lefkofsky isn’t allowing his work to get ahead of him, but he also points out how important it all is. Lefkofsky believes that Tempus is at the forefront of a true paradigm shift in the healthcare industry.